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Abstract 
Liver disease is now the third most common cause of premature death in the UK, with 
chronic viral hepatitis being an important contributory factor. Often the diagnosis of 
chronic liver disease is only made when patients present late in the disease trajectory. 
This underscores the importance of near patient testing and linkage into care.  The 
need for community based models for liver disease is in line with the recently 
commissioned National Liver report, which calls for assessment and treatment of 
high-risk individuals in the community.  
 
In this manuscript our objectives are to discuss the need for community services for 
individuals with hepatitis C virus (HCV) infection and give an overview of the 
different community models for HCV. Finally we describe our experiences in setting 
up a successful nurse led service for screening, stratification and treatment of HCV 
related liver disease at a substance misuse service. We highlight the important stages 
of this process including engaging with stakeholders, obtaining funding and service 
set up. We also explore the obstacles and challenges faced and summarise our key 
recommendations. A brief summary of interim clinical outcomes is also presented.  
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Background and aims 
Liver disease is the third most common cause of premature death in the UK (Williams 
et al., 2014). Chronic hepatitis C virus (HCV) infection remains a major national 
health burden (HCV in England 2017 report, 2017) with an estimated 160,000 
individuals infected (Harris et al., 2012). Globally, deaths from viral hepatitis (1.4 
million/yr) have now surpassed that of HIV (1.3 million/yr), and malaria (1.2 
million/yr) and TB (0.5 million/yr) combined (Global Burden of Disease and 
WHO/UNAIDS estimates.; 2015). This mandated the first ever WHO Global Health 
Sector Strategy (GHSS) in May 2016, which aims for elimination of viral hepatitis by 
2030 (WHO, 2016). The vision statement of Public Health England (PHE) 2017 
Hepatitis C report is in line with the WHO GHSS (HCV in England 2017 report, 
2017).  
 
Injecting drug use is responsible for 90% of all HCV infections in England (HCV in 
England 2017 report, 2017), with 52% of people who inject drugs (PWID) having a 
positive HCV serology (PHE HCV in England 2017 Headline data table, 2017). PHE 
estimates that about 50% of individuals with HCV may have already been diagnosed  
(HCV in England 2017 report, 2017), however only 53% PWID sampled are aware of 
their HCV antibody positivity status (People who inject drugs UAMS Survey, 2017).  
 
Due to the advent of direct acting antivirals (DAAs), there has been a paradigm shift 
in the management of chronic HCV infection. DAAs have sustained virological 
response (SVR) rates (i.e. cure) in the high 90% despite shorter durations of treatment 
(on average 12 weeks), and are effective orally (Bell et al., 2016; Feld at al., 2014; 
Feld at al., 2015; Kowdley et al., 2014). In England, From June 2015-April 2016, 
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38% more individuals (7,036) accessed treatment (Interim Clinical Commissioning 
Policy Statement, 2014 and Clinical Commissioning Policy Statement, 2015) than 
mean 2008-2014 levels (PHE HCV in England 2017 report, 2017).  This may have 
contributed to the 8% reduction in deaths from HCV related ESLD and HCC (PHE 
HCV in England 2017 report, 2017) and 38% reduction in liver transplantation (38%) 
in 2015 (UK Transplant Registry, 2017.  DAA treatment outcomes in PWID are 
comparable to those in secondary care (Dore et al., 2016).  
 
Despite the discovery of DAAs however, we still need a three-five-fold increase in 
HCV diagnosis and treatment if we are to stem the national HCV burden (Wedemeyer 
et al., 2014). However, PWID remain a vulnerable cohort with poor engagement with 
hospital services  
 
The objectives of this manuscript are to present the need for community HCV 
services for PWID, give an overview of the different community models for HCV and 
finally describe our experiences in setting up a successful nurse led HCV service at a 
substance misuse service (SMS). Detailed outcome data will not be presented in this 
manuscript as final data analysis (clinical, qualitative, patient reported and health 
economic outcomes) will be completed mid 2018 and with the aim to publish in a  
Hepatology focussed journal. However, a brief summary of interim clinical outcomes 
is provided.  
HCV community service development  
Stage 1: Establishing a need 
Economic modeling suggests that prioritizing HCV treatment in PWID with a <40% 
HCV seroprevalence and mild to moderate liver disease (in combination with opioid 
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substitution therapy (OST)/needle and syringe programs) is more cost-effective than 
treating other patient groups because of the additional benefit of avoiding onwards 
transmission also known as “treatment as prevention” (Martin et al., 2013; Martin et 
al., 2016). 
An earlier study from Nottingham however showed that overall only 49% of 
individuals with a positive HCV serology were referred to a specialist, 27% attended 
and 10% were treated (Irving et al.; 2006). A re audit about 10 years later showed 
improvement (80% referred, 70% attended and 38% commenced treatment) though 
clearly there remained scope for improvement (Howes et al.; 2016). Barriers to HCV 
treatment remain at all levels of care (patient, provider and national) (see Fig 1). 
These include the complex nature of HCV treatment (until recently), inability of 
health care providers to appreciate the complex needs of vulnerable PWID, perceived 
stigmatisation and reluctance to treat those actively engaged in alcohol and substance 
misuse (Irving et al.; 2006, Marufu et al., 2011; Dillon.; 2016). 
 
Locally and as reported by others (Mehta et al., 2008; Lewis et al., 2016) we have 
been cognisant of the poor uptake of HCV services by PWID.  In 2011 we appointed 
a hepatitis nurse at the largest SMS in Brighton to perform blood dry blood spot 
testing (DBST) for blood borne virus (BBV) screening with onward referral to 
Hepatology services. Over a six-month period, of those identified with a positive 
BBV screen (n=73), 14 (19.1%) were known to Hepatology services  (two previously 
treated).  Of the forty individuals suitable for antiviral treatment, only two (5%) 
engaged with secondary care (42% declined a referral and 37% disengagement with 
SMS). No individual was eventually treated (Marufu et al., 2012). Poor uptake of 
HCV treatment may be contributing to Brighton and Hove having the highest hospital 
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admission /100,000 population with HCV related end stage liver disease (ESLD) and 
hepatocellular cancer (HCC) (4.8, 95% CI 3.4-6.5), and highest mortality in those 
aged < 75yrs from HCV related ESLD and HCC (1.39, 95% CI 0.70-2.49) in the 
south east (PHE fingertips).  
 
These data indicates the value of developing innovative community HCV services. 
Such a novel strategy would represent patient-centred care with earlier diagnosis and 
treatment, prevention of onwards-viral transmission and potential for reduction in 
health inequalities. A community-based model with linkage to care is in line with the 
recently commissioned National Liver Report that advocates screening and treatment 
for chronic liver disease in the community (Williams et al., 2014).  
 
NHS targets are to treat 10,000 individuals with HCV infection in 2016, increasing to 
15,000/year in 2020 (PHE HCV in England report, 2017). If achieved, statistical 
modelling predicts that around 2620 people would be living with HCV-related 
cirrhosis or HCC (a 81% reduction) in England by 2030 (Harris et al., 2016) as 
mandated by the WHO (WHO, 2016). This is however unlikely to be achieved without 
engaging PWID. 
 
2. Overview of HCV community models of care 
The model of specialist hepatitis nurses working in SMS/drug and alcohol services 
has been implemented before, though care has been fragmented, with BBV screening 
at SMS followed by referral to secondary care (Marufu et al., 2012); Even if nurse led 
treatment has been provided at SMS it is often delivered via out-reach intermittent 
clinics (Selvapatt et al., 2016) and does not always include assessment of hepatic 
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fibrosis (Grebely et al., 2016). In other models, homeless individuals attending 
addiction centres underwent review by a consultant Hepatologist and a hepatitis nurse 
but again only on an intermittent (monthly) basis (Wilkinson et al., 2009). Directly 
Observed Therapy (DOT) with pegylated interferon (peg-IFN) and ribavirin (RBV) 
have also been incorporated into opioid substitution clinics (Bonkovsky et al., 2008). 
Nonetheless, these DOT models are limited to small randomised controlled trials and 
involve close collaboration with secondary and tertiary services- not always feasible 
in a community setting (Bruggmann & Litwin, 2013).  
 
Group or peer based treatment has also been trialled, in which an experienced peer co 
leads the treatment along with a medical provider. This has led to successful treatment 
outcomes in various settings but relies on pre-treatment engagement (Sylvestre & 
Clements, 2007). In addition, this model is dependent on excellent group dynamics 
and effective communication between the peers (Bruggmann & Litwin, 2013). 
In the General Practitioner (GP) based model, a GP with additional HCV training 
offers treatment to PWIDs alongside OST (Seidenberg et al., 2013). While this model 
is simple, provision of addiction and HCV treatment by a single GP is demanding and 
requires great commitment, effort and training of the primary care provider 
(Seidenberg et al., 2013). Other primary care strategies employed a specialist nurse 
working in general practices (Jack et al., 2009), but many PWIDs do not engage with 
their GPs. The Australians however have managed to treat > 20,000 individuals with 
HCV infection during Mar-Jun 2016 (previously 2,000-3,000 patients treated per/yr). 
Multiple factors contributed to this phenomenal success including prescribing by GPs 
(Kirby Institute, Australia, 2016). In a recent on-going study in South West England, 
patients in 46 general practices are being randomised to receive either standard care or 
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a complex intervention comprising educational training, posters and leaflets display, 
the aim being to raise awareness and encourage opportunistic testing through risk 
prediction algorithms (Roberts et al., 2016).  
 
Other established community HCV programmes such as the American ECHO (The 
Extension for Community Healthcare Outcomes) project have also shown great 
success (Arora et al., 2010). This model links Hepatologists with primary care 
physicians in local communities via telehealth technology. It allows optimal 
management of HCV patients through “knowledge networks,” bringing together 
expert interdisciplinary specialists from the hospital and multiple community-based 
primary care practitioners (Arora et al., 2010). Similar outcomes have also been 
shown in the Veteran Affairs –ECHO programme (Beste et al., 2016). Other 
innovative strategies include the French mobile hepatitis team (Remy et al., 2016). 
Table 1 summarises the pros and cons of the different community HCV models 
 
Stage 2: Obtaining funding and assembling team 
 
Having identified a clear unmet need to link PWID into care by developing a 
community HCV service model, we then engaged with various stakeholders [SMS, 
psychiatrists, patient groups (Hepatitis C Trust, British Liver Trust), Brighton and 
Hove Commissioners, and Pharma]. 
 
Our aim was to set up a unique “one-stop” HCV community clinic that provided all 
components of care (BBV screening, stratification of hepatic fibrosis, nurse-led HCV 
treatment under Hepatologist supervision, hepatitis B vaccination, OST and social and 
psychiatric input) at one site. In view of the complex needs of PWID our philosophy 
was that an integrated and multidisciplinary model based at a SMS had the best 
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chance of success. We selected this model rather than one based in primary care due 
to  
- Our prior established links with the SMS enabling us to engage PWID in an 
environment they were comfortable in 
- A recent meta-analysis identifying “treatment of addiction during HCV 
therapy” as a factor associated with higher treatment completion (Dimova et 
al., 2012)   
- A historical reluctance by GPs in England to be involved in antiviral 
prescription. 
 
In 2013, we obtained funding for two years (National Gilead Fellowship and Brighton 
and Hove Commissioners) to set up our community hepatitis C service at the SMS in 
Brighton (Sussex Partnership Trust). In 2015 additional funding from the same 
sources extended our work for two years (until Dec 2017). The funding allowed for 
appointment of a band 7-community hepatitis nurse and a health economics and 
qualitative researcher, mobile fibroscan  purchase and data collection (clinical, 
qualitative, patient reported and health economic outcomes). The Fibroscan (fig 2) is 
a non-invasive painless liver scan that utilises liver stiffness as a measurement of 
severity of liver fibrosis (Sandrin et al., 2003). It is now a validated technique 
(sensitivity and specificity 80~90%) for detection of all stages of liver fibrosis in 
individuals with most aetiologies of chronic liver disease including HCV (Sandrin et 
al., 2003; Talwalkar et al., 2007).  
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Stage 3: Service set up 
This involved training of the hepatitis nurse (MOS), identification of a lead 
psychiatrist at the SMS (HW), and detailed discussions with managers at SMS to 
address logistic issues including clinic space. The service was publicised by the on-
going engagement with stakeholders, MOS engaging with SMS staff and use of 
posters. In addition, both MOS and SV attended the monthly Substance Misuse 
Board, chaired by the Commissioners and usually well attended by various 
stakeholders. Fig 3 summarises the stages in setting up the community HCV service.                                                                                                                                
 
Prerequisites for a successful HCV community service  
In our view the following were prerequisites for a successful HCV community 
service: 
- An integrated and multidisciplinary approach with provision of all 
components of the service at one site, preferably a SMS  
- An experienced community hepatitis nurse additionally trained in substance 
misuse and passionate about working with this client group to provide holistic 
care 
- Easy access to nurse (mobile phone) and close supervision by a Hepatologist  
- Flexible clinic appointments in contrast to the inflexible, non-personalised and 
stigmatised environment in secondary care.  
- Community Fibroscan for non-invasive staging of hepatic fibrosis 
- Presence of onsite psychiatrist 
- On going alcohol and drug use not a bar to HCV treatment  
- Personalised strategies for drug delivery  (e.g. home delivery) 
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- Provision of peer advocates (buddies) to support clients throughout their 
treatment journey. 
- Good engagement between key workers, drug and alcohol team, psychiatrist, 
peer advocates and hepatitis nurse. 
- Non judgemental approach  
 
The role of the hepatitis nurse is summarised in Fig 4 and participant pathway in Fig. 
5 
 
4. Delivery logistics and barriers to success  
Though the need for a community service was greatly appreciated, set up was 
associated with a variety of issues that included  
- Scepticism  “ it ain’t going to work”  
- Concerns about treating those with on-going drug and alcohol use “can’t be 
trusted with expensive drugs” 
- Misconceptions about treatment efficacy and reinfection risks in PWID  
- Logistic issues especially lack of clinical space. Not infrequently clinical 
space had to be shared with the consultant psychiatrist. A change in providers 
in 2015 (Surrey and Borders) meant relocating the service to new premises. 
This heightened the issues of availability of clinical rooms, and there are on-
going negotiations with management and clinical staff to resolve this problem. 
- Concerns that interactions between the community hepatitis nurse, 
psychiatrist, and key workers would be incongruent.  
- Remote access to hospital pathology and radiology database - this was 
resolved with the use of a laptop and remote modem.  
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- On-going need to train the staff at the SMS in BBV testing and providing 
them with the latest HCV treatment updates. This required not only regular 
training of the substance misuse teams but also reaching out to the wider 
community to include volunteers, peer mentors, those running 
Narcotics/Alcohol Anonymous meetings, homeless hostel workers, 
rehabilitation units staff and GP’s. We are now in fact part of the GP rotation-
teaching programme and provide update sessions to GPs on a regular basis 
highlighting the changes in HCV treatment and the criteria for referral to our 
service. In the past PWID would have been denied HCV treatment and so it is 
essential to dispel this antiquated myth amongst the medical and the wider 
community. 
- Restrictive access to DAA due to prohibitive costs. The Early Access 
Programme (EAP) enabled treatment of those with decompensated cirrhosis 
due to a high probability of death and or irreversible damage within a year  
(Interim Clinical Commissioning Policy Statement, 2014). NHS England then 
extended treatment to cirrhotics (Clinical Commissioning Policy Statement, 
2015) and subsequently to those with advanced fibrosis (LSM > 9.5 kPa). 
There are however exceptional criteria to include those with extra hepatic 
disease and PWID (as window of opportunity). Treatment can only be 
dispensed through nationally selected ODNs (n=22), of which we are one. 
Each patient is discussed at a weekly multidisciplinary meeting (MDM). Each 
genotype has a first choice regimen and all second choice drugs (which in fact 
maybe more appropriate) need “buddy ODN” approval. There are severe 
financial penalties for the ODN if guidelines are breached. Each ODN has 
been provided with a run rate based on the regional prevalence of HCV and 
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again, there are financial penalties for exceeding this. While each ODN can 
treat a subset of patients (10-20%) under the exceptional criteria, this remains 
highly scrutinised. It is therefore frustrating that despite effective antivirals 
and engaged SMS clients who often only have a small window of opportunity; 
we are still unable to offer treatment to a substantial number of PWID. This is 
in sharp contrast to countries like Australia where there is unrestricted access 
to DAA (including for re-infection) and primary care physicians are 
encouraged to take on prescribing and treatment as already stated (Kirby 
Institute, Australia, 2016). We have now initiated discussions to incentivise 
ODN that develop community out-reach programmes (for e.g. increased run 
rates). 
- Need for upfront funding for service set up – this has somewhat been negated 
by establishment of ODN and availability of CQUIN funds 
 
5. Evaluating the service 
 
We aimed to evaluate this community based HCV service through collection of 
following data: 
1. Clinical: demographics, drug and alcohol use, uptake of DBST, HBV 
vaccination and HCV treatment as well as treatment outcomes 
2. Qualitative:  Conduct of interviews with SMS attendees and two focus groups 
with staff members  
3.  Patient reported outcomes using validated questionnaires 
a. Liver related quality of life (QOL) - Short-form Liver Disease 
Quality of Life (SF-LDQOL) (LDQOL; Kanwal et al., 2008) 
b. Non-disease specific health related outcomes - SF-12v2, which is a 
shortened form (12 items) of the SF-36v2 Health Survey (SF-36) 
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4.   Assessment of quality adjusted life years (QALY) using EQ-5D-5L (EQ-5D-5L 
survey) and perform a health economics (HE) assessment (cost per cure) 
 
6. Progress 
 
As already stated, detailed outcome data will not be presented in this manuscript. Our 
year 3 interim clinical outcomes have been selected for presentation at the American 
Association for Study of Liver Disease meeting (2017) and these are summarised 
below.  
- To date, 485 individuals have been recruited, 80% (n=388) males, mean age 
41.0 + 9.9 yrs. 
-  Prevalence of injecting drug use (IDU) [336 (69%)], alcohol use [416 (86%)] 
and psychiatric illness [225(47%)] remains high.  
- Uptake of DBST was 97% (n=472). Prevalence of positive serological 
markers/PCR were: HBcAb 20% (n=88), HCV antibody 56% (n=262) and 
HCV PCR 81% (211/262); genotypes 1=92 (44%) and 3= 94 (44%) 
-  Independent predictors of a positive HCV serology were age, if ever injected, 
positive HBcAb and if ever had a psychiatric diagnosis (p value for all 
<0.003).   
- Of those with a positive HCV PCR (n=211), 169 (80%) underwent transient 
elastography (TE) [median liver stiffness measurement (LSM) 6.8 kPa (2.7-
75], 76 (45%) having significant fibrosis (LSM >7.5 kPa, with 42 (25%) 
having cirrhosis. 
-  Sixty-six (31%) individuals were not treatment candidates (chaotic lifestyle), 
87/145 (60%) of the remaining with a positive PCR commencing HCV 
treatment in the community.  
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- Characteristics of treated cohort were: age 46 + 9.2 yrs; 84% male; 29% and 
20% having on going alcohol and IDU respectively; 95% undergoing TE 
[median LSM 8.7 kPa (2.7-75), 39% (34) having cirrhosis including four with 
decompensation];  
- Genotypes 1 = 48%, 3= 45% 
- Treatment received: INF/RBV 18%, INF+DAA 21% and DAA 61% 
- Treatment outcomes were:  sustained virological response (SVR12) (47, 54%), 
end of treatment response (EOTR) awaiting SVR12 (12, 14%), nonresponse 
(NR) (4, 4%),  responder relapse (RR) (5, 6%), and on going treatment (19, 
22%).  All but one NR/RR received INF based treatment 
- Compliance with treatment was 97% 
- No reinfection till date (O’Sullivan et al., 2017) 
 
Project ITTREAT has also been presented at earlier national and international 
conferences (O’Sullivan et al., 2015; O’Sullivan et al., 2016; O’Sullivan et al., 2016) 
and was selected by PHE as a showcase for good clinical practice (HCV Action and 
PHE Hepatitis C Roadshow), 2015). Currently our managers are drafting a business 
case to allocate CQIN funds for permanency of the community hepatitis nurse post 
once funding runs out end of 2017. We are also exploring extension of the community 
hepatitis nurse role to include management of individuals with other forms of chronic 
liver disease including those with cirrhosis. 
 
Based upon the success of Project ITTREAT our team has now established the 
VALID (Vulnerable Adult LIver Disease) project. This is a similar integrated 
community liver service based at two homeless hostels and offers non-invasive 
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assessment of hepatic fibrosis (Fibroscan) followed by targeted treatment for chronic 
liver disease including for BBV (Hashim et al., 2016). NHS England have selected 
the VALID study for inclusion on a website which is a showcase for good practice 
(Learning Environment – NHS England, 2016). 
 
Conclusions and the future 
 
Linking PWIDs into care is essential if HCV infection is to be eliminated by 2030 as 
set out in the WHO strategy. These individuals have however consistently failed to 
access traditional models of secondary care. The advent of DAA provides an 
unprecedented opportunity to address the national HCV burden.   Our integrated and 
multidisciplinary community models of care (Project ITTREAT, VALID Study) have 
been successful in engaging such individuals with outcomes comparable to secondary 
care, despite the complex nature of the cohort. Provision of all aspects of the care at 
one site, a dedicated and highly motivated team and the excellent communication 
between them and substance misuse staff, other community services, and stakeholders 
is the key to the success of this service. Our easy to replicate community HCV models 
have the potential for national adoption. 
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Table 1 Pros and cons of different community based HCV models of care 
 
Community Model Advantages Limitations 
Models based in General 
Practices. 
(Seidenberg et al., 2013; Jack 
et al., 2009) 
Easy to establish and  
incorporates HCV  and 
addiction treatment 
Require extensive training 
of GPs 
 
Directly Observed 
Treatment in substance 
misuse services 
(Bonkovsky et al., 2008) 
Established evidence of 
enhanced adherence 
Only small numbers can 
be achieved and often 
combined with secondary 
and tertiary referrals 
Peer/group based 
treatment 
(Sylvestre & Clements, 2007) 
Potentially improves 
compliance and enhances 
patient motivation. 
Relies on positive pre-
treatment engagement and 
group dynamics 
 
Hepatitis specialist nurse 
in addiction units 
(Selvapatt et al., 2016; 
Wilkinson et al., 2009) 
Offers specialist input with 
ability to screen and treat 
large numbers of patients. 
 
Lacked of an integrated 
and multidisciplinary 
approach including non-
invasive assessment of 
hepatic fibrosis 
ECHO (Extension for 
Community Healthcare 
Outcomes) model  
(Arora et al., 2010;  Beste et 
al., 2016) 
Widely accepted and 
validated  
 Requires frequent 
networking between GPs 
and Hepatologists 
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Fig 1. Barriers to care in individuals with hepatitis C virus infection  
 
 
Patient level  
1. Majority are PWID with poor engagement with secondary care due to 
chaotic life style and competing priorities   
2. Asymptomatic nature of the disease 
3. Perceived stigmatisation and prior negative experiences with health 
services 
4. Myths associated with antiviral treatment and liver biopsy 
 
Provider level 
1. Failure to understand complex needs of PWID  
2.  Lack of awareness, hence not a priority for health care professionals 
3. Bureaucratic and inflexible hospital environment  
4. Prejudice and reluctance to treat those with on going alcohol and drug use 
5. Misconceptions regarding treatment efficacy and reinfection in PWID 
6. Lack of multidisciplinary approach with suboptimal interactions between 
addiction specialists and Hepatologists 
 
National level 
1. Restricted access to antiviral drugs 
2. Lack of accurate data on HCV epidemiology 
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Fig. 2 Portable FibroScan® 402 device 
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Fig 3 Stages in developing a community HCV service  
 
  
 
 
 
 
*HE       = Health Economics 
**PRO   = Patient Reported Outcomes 
***PHE   = Public Health England 
 
 
 
 
 
 
 
 
 
 
 
 
 
Establishing need for community HCV 
service 2011
Engaging with stakeholders to include  
Commissioners, Hepatitis C Trust, British 
Liver Trust, Substance Misuse Service, 
Pharmaceutical industry 2011-2013
Developing the team: Hepatologist, 
Community nurse,  Psychiatrist, 
Qualitative researcher, 
statistician,2011-2013
Successful two year funding to appoint 
community nurse and qualitative 
researcher, purchase mobile fibroscan 2013
4 85 individuals recruited, 97% uptake 
of BBV testing/compliance with HCV 
treatment.  Work presented at national 
and international liver meetings and 
selected by PHE*** for presentation as 
good practice  model 
Additional 2 yr 
funding  for 
nurse and to 
include HE* and 
PRO** 
2015 
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Fig 4. Role of community hepatitis nurse 
 
1. Testing for BBVs using DBST (dried blood spot testing), including 
confirmatory PCR for those who screen positive 
2. Perform community based transient elastography for non-invasive assessment 
of hepatic fibrosis 
3. Identify clients suitable for HCV treatment. Those with on going alcohol and 
substance misuse not excluded from treatment as long as willing to engage 
and stable housing. 
4. Monitor HCV treatment under supervision of a Hepatologist.  
5. Hepatitis B virus vaccination for those not immune 
6. Work closely with psychiatrist, substance misuse counsellors, key workers and 
peer advocates to ensure holistic care including with social issues (housing 
etc) 
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Fig 5: Project ITTREAT: Participant pathway  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SMS substance misuse service, BBV blood borne viruses; DBST direct blood spot testing, PCR 
polymerase chain reaction, TE transient elastography, USG ultrasound, OGD 
oesophagogastroduodenoscopy, PRO patient reported outcomes, HE health economics, SVR sustained 
virological response 
 
 
 
 
P Participant attends drop in liver clinic based at SMS and undergoes BBV screening using 
DBST/PCR. Advised on safe injecting, engagement with key worker and provided mobile 
phone number for community hepatitis nurse (CHN) 
  
 Negative Ab – Follow up at 
SMS 
Positive HCV antibody (Ab) – 
Test for PCR 
 Negative HCV PCR – Follow 
up at SMS 
 Positive HCV PCR – Undergo Liver screen, 
TE, liver screen, USG and OGD if indicated  
Assess if stable for HCV treatment 
 Not suitable for HCV treatment 
-   CHN continues to monitor 
 Suitable for HCV treatment - 
Assessed by Hepatologist at SMS 
and discussed at Hospital MDT 
Participant fulfils 
national/exceptional 
criteria 
 Commence HCV treatment 
at SMS, clinical, PRO and 
HE data collection 
 CHN monitors and 
assesses for SVR 12  Encourage yearly HCV PCR   
Peer advocates (buddy) support participants throughout their journey 
